Macromolecular glucocorticoid prodrug improves the treatment of dextran sulfate sodium-induced mice ulcerative colitis

Clinical Immunology

Volumn 160, Issue 1, 2015, Pages 71-81

  Ren, Ke ^a   Yuan, Hongjiang ^a   Zhang, Yijia ^a   Wei, Xin ^a   Wang, Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Dextran sulfate sodium; ELVIS; Glucocorticoid; HPMA copolymer; Inflammatory bowel diseases; Prodrug

Indexed keywords

DEXAMETHASONE; DEXTRAN SULFATE; PHOSPHATE BUFFERED SALINE; POLYMER; PRODRUG; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; GLUCOCORTICOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; EPITHELIUM CELL; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LOOSE FECES; MACROMOLECULE; MALE; MOUSE; NONHUMAN; PHARMACEUTICAL EQUIVALENCE; PRIORITY JOURNAL; RECTUM HEMORRHAGE; SCORING SYSTEM; SINGLE DRUG DOSE; ULCERATIVE COLITIS; WEIGHT REDUCTION; ANIMAL; CACO 2 CELL LINE; CELL LINE; COLITIS, ULCERATIVE; COLON; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; PATHOLOGY; RANDOMIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; CACO-2 CELLS; CELL LINE; COLITIS, ULCERATIVE; COLON; DEXAMETHASONE; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GLUCOCORTICOIDS; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MACROPHAGES; MALE; MICE; PRODRUGS; RANDOM ALLOCATION;

EID: 84940447445     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.027     Document Type: Article

References (44)

1. Lakatos P.L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World J. Gastroenterol. 2006, 12(38):6102-6108.
2. Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011, 140(6):1785-1794.
3. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3(7):390-407.
4. Fiocchi C. Inflammatory bowel disease: evolutionary concepts in biology, epidemiology, mechanisms and therapy. Curr. Opin. Gastroenterol. 2013, 29(4):347-349.
5. Abraham C., Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361(21):2066-2078.
6. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347(6):417-429.
7. Melgar S., Shanahan F. Inflammatory bowel disease-from mechanisms to treatment strategies. Autoimmunity 2010, 43(7):463-477.
8. Lichtenstein G.R., Abreu M.T., Cohen R., Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130(3):940-987.
9. Sohrabpour A.A., Malekzadeh R., Keshavarzian A. Current therapeutic approaches in inflammatory bowel disease. Curr. Pharm. Des. 2010, 16(33):3668-3683.
10. Katz J.A. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol. Clin. N. Am. 2004, 33(2):171-189. (vii).
11. Benchimol E.I., Seow C.H., Steinhart A.H., Griffiths A.M. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2008, (2):CD006792.
12. Moghadam-Kia S., Werth V.P. Prevention and treatment of systemic glucocorticoid side effects. Int. J. Dermatol. 2010, 49(3):239-248.
13. Schacke H., Docke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002, 96(1):23-43.
14. Liu X.M., Quan L.D., Tian J., Alnouti Y., Fu K., Thiele G.M., et al. Synthesis and evaluation of a well-defined HPMA copolymer-dexamethasone conjugate for effective treatment of rheumatoid arthritis. Pharm. Res. 2008, 25(12):2910-2919.
15. Wang D., Miller S.C., Liu X.M., Anderson B., Wang X.S., Goldring S.R. Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res. Ther. 2007, 9(1):R2.
16. Ren K., Purdue P.E., Burton L., Quan L.D., Fehringer E.V., Thiele G.M., et al. Early detection and treatment of wear particle-induced inflammation and bone loss in a mouse calvarial osteolysis model using HPMA copolymer conjugates. Mol. Pharm. 2011, 8(4):1043-1051.
17. Yuan F., Nelson R.K., Tabor D.E., Zhang Y., Akhter M.P., Gould K.A., et al. Dexamethasone prodrug treatment prevents nephritis in lupus-prone (NZB×NZW)F1 mice without causing systemic side effects. Arthritis Rheum. 2012, 64(12):4029-4039.
18. Ren K., Dusad A., Yuan F., Yuan H., Purdue P.E., Fehringer E.V., et al. Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects. J. Control. Release 2013, 175C:1-9.
19. Henson P.M. Dampening inflammation. Nat. Immunol. 2005, 6(12):1179-1181.
20. Nishiyama Y., Kataoka T., Yamato K., Taguchi T., Yamaoka K. Suppression of dextran sulfate sodium-induced colitis in mice by radon inhalation. Mediat. Inflamm. 2012, 2012:239617.
21. Tanaka K., Namba T., Arai Y., Fujimoto M., Adachi H., Sobue G., et al. Genetic evidence for a protective role for heat shock factor 1 and heat shock protein 70 against colitis. J. Biol. Chem. 2007, 282(32):23240-23252.
22. Kim C.J., Kovacs-Nolan J., Yang C., Archbold T., Fan M.Z., Mine Y. L-cysteine supplementation attenuates local inflammation and restores gut homeostasis in a porcine model of colitis. Biochim. Biophys. Acta 2009, 1790(10):1161-1169.
23. Dieleman L.A., Palmen M.J., Akol H., Bloemena E., Pena A.S., Meuwissen S.G., et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 1998, 114(3):385-391.
24. Quan L.D., Purdue P.E., Liu X.M., Boska M.D., Lele S.M., Thiele G.M., et al. Development of a macromolecular prodrug for the treatment of inflammatory arthritis: mechanisms involved in arthrotropism and sustained therapeutic efficacy. Arthritis Res. Ther. 2010, 12(5):R170.
25. Ren K., Dusad A., Yuan F., Yuan H., Purdue P.E., Fehringer E.V., et al. Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects. J. Control. Release 2014, 175:1-9.
26. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995, 270(5234):283-286.
27. Tao Y., Williams-Skipp C., Scheinman R.I. Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis. J. Biol. Chem. 2001, 276(4):2329-2332.
28. Barnes P.J. Glucocorticosteroids: current and future directions. Br. J. Pharmacol. 2011, 163(1):29-43.
29. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 2005, 353(16):1711-1723.
30. Nikhil Singh M.J.R., Jane Tucker M. Mechanisms of glucocorticoid-mediated antiinflammatory and immunosuppressive action. Paediatr. Perinat. Drug Ther. 2004, 6(2):107-115.
31. Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993, 69(2):238-249.
32. Kang O.H., Kim D.K., Choi Y.A., Park H.J., Tae J., Kang C.S., et al. Suppressive effect of non-anaphylactogenic anti-IgE antibody on the development of dextran sulfate sodium-induced colitis. Int. J. Mol. Med. 2006, 18(5):893-899.
33. Silbermann M., Kleinhaus U., Livne E., Kedar T. Retardation of bone growth in triamcinolone-treated mice. J. Anat. 1976, 121(Pt 3):515-535.
34. Ortoft G., Gronbaek H., Oxlund H. Growth hormone administration can improve growth in glucocorticoid-injected rats without affecting the lymphocytopenic effect of the glucocorticoid. Growth Horm. IGF Res. 1998, 8(3):251-264.
35. Allen D.B., Mullen M., Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J. Allergy Clin. Immunol. 1994, 93(6):967-976.
36. Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2(3):541-546.
37. Kawada M., Arihiro A., Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J. Gastroenterol. 2007, 13(42):5581-5593.
38. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv. Drug Deliv. Rev. 2007, 59(11):1073-1083.
39. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98(3):694-702.
40. Mahler M., Bristol I.J., Leiter E.H., Workman A.E., Birkenmeier E.H., Elson C.O., et al. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am. J. Physiol. 1998, 274(3 Pt 1):G544-G551.
41. Laroui H., Ingersoll S.A., Liu H.C., Baker M.T., Ayyadurai S., Charania M.A., et al. Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS One 2012, 7(3):e32084.
42. Dieleman L.A., Ridwan B.U., Tennyson G.S., Beagley K.W., Bucy R.P., Elson C.O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994, 107(6):1643-1652.
43. Oh S.Y., Cho K.A., Kang J.L., Kim K.H., Woo S.Y. Comparison of experimental mouse models of inflammatory bowel disease. Int. J. Mol. Med. 2014, 33(2):333-340.
44. Byrne F.R., Viney J.L. Mouse models of inflammatory bowel disease. Curr. Opin. Drug Discov. Dev. 2006, 9(2):207-217.